These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 17951980)

  • 1. Antiplatelet effect of NQ12: a possible mechanism through the arachidonic acid cascade.
    Jin YR; Han XH; Lee JJ; Lim Y; Kim TJ; Yoo HS; Hong JT; Lee CK; Yun YP
    J Pharmacol Sci; 2007 Oct; 105(2):193-200. PubMed ID: 17951980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An antithrombotic agent, NQ301, inhibits thromboxane A2 receptor and synthase activity in rabbit platelets.
    Jin YR; Cho MR; Lee KS; Lee JJ; Lim Y; Han XH; Oh KW; Hong JT; Yoo HS; Yun YP
    Basic Clin Pharmacol Toxicol; 2005 Sep; 97(3):162-7. PubMed ID: 16128910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiplatelet activity of J78 (2-Chloro-3-[2'-bromo, 4'-fluoro-phenyl]-amino-8-hydroxy-1,4-naphthoquinone), an antithrombotic agent, is mediated by thromboxane (TX) A2 receptor blockade with TXA2 synthase inhibition and suppression of cytosolic Ca2+ mobilization.
    Jin YR; Cho MR; Ryu CK; Chung JH; Yuk DY; Hong JT; Lee KS; Lee JJ; Lee MY; Lim Y; Yun YP
    J Pharmacol Exp Ther; 2005 Jan; 312(1):214-9. PubMed ID: 15328379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiplatelet activity of carnosol is mediated by the inhibition of TXA2 receptor and cytosolic calcium mobilization.
    Lee JJ; Jin YR; Lim Y; Hong JT; Kim TJ; Chung JH; Yun YP
    Vascul Pharmacol; 2006 Sep; 45(3):148-53. PubMed ID: 16916624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The protective effects of paclitaxel on platelet aggregation through the inhibition of thromboxane A2 synthase.
    Lee JJ; Yu JY; Lee JH; Zhang WY; Kim TJ; Myung CS; Yun YP
    Arch Pharm Res; 2010 Mar; 33(3):387-94. PubMed ID: 20361303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism for antiplatelet effect of onion: AA release inhibition, thromboxane A(2)synthase inhibition and TXA(2)/PGH(2)receptor blockade.
    Moon CH; Jung YS; Kim MH; Lee SH; Baik EJ; Park SW
    Prostaglandins Leukot Essent Fatty Acids; 2000 May; 62(5):277-83. PubMed ID: 10883058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antithrombotic and antiplatelet activities of 2-chloro-3-[4-(ethylcarboxy)-phenyl]-amino-1,4-naphthoquinone (NQ12), a newly synthesized 1,4-naphthoquinone derivative.
    Yuk DY; Ryu CK; Hong JT; Chung KH; Kang WS; Kim Y; Yoo HS; Lee MK; Lee CK; Yun YP
    Biochem Pharmacol; 2000 Oct; 60(7):1001-8. PubMed ID: 10974210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiplatelet activity of epigallocatechin gallate is mediated by the inhibition of PLCgamma2 phosphorylation, elevation of PGD2 production, and maintaining calcium-ATPase activity.
    Jin YR; Im JH; Park ES; Cho MR; Han XH; Lee JJ; Lim Y; Kim TJ; Yun YP
    J Cardiovasc Pharmacol; 2008 Jan; 51(1):45-54. PubMed ID: 18209568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NP-184[2-(5-methyl-2-furyl) benzimidazole], a novel orally active antithrombotic agent with dual antiplatelet and anticoagulant activities.
    Kuo HL; Lien JC; Chung CH; Chang CH; Lo SC; Tsai IC; Peng HC; Kuo SC; Huang TF
    Naunyn Schmiedebergs Arch Pharmacol; 2010 Jun; 381(6):495-505. PubMed ID: 20349046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiplatelet effect of green tea catechins: a possible mechanism through arachidonic acid pathway.
    Son DJ; Cho MR; Jin YR; Kim SY; Park YH; Lee SH; Akiba S; Sato T; Yun YP
    Prostaglandins Leukot Essent Fatty Acids; 2004 Jul; 71(1):25-31. PubMed ID: 15172681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiplatelet activity of hesperetin, a bioflavonoid, is mainly mediated by inhibition of PLC-gamma2 phosphorylation and cyclooxygenase-1 activity.
    Jin YR; Han XH; Zhang YH; Lee JJ; Lim Y; Chung JH; Yun YP
    Atherosclerosis; 2007 Sep; 194(1):144-52. PubMed ID: 17092506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New developments on thromboxane and prostacyclin modulators part I: thromboxane modulators.
    Dogné JM; de Leval X; Hanson J; Frederich M; Lambermont B; Ghuysen A; Casini A; Masereel B; Ruan KH; Pirotte B; Kolh P
    Curr Med Chem; 2004 May; 11(10):1223-41. PubMed ID: 15134516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel angiotensin II AT(1) receptor antagonist irbesartan prevents thromboxane A(2)-induced vasoconstriction in canine coronary arteries and human platelet aggregation.
    Li P; Fukuhara M; Diz DI; Ferrario CM; Brosnihan KB
    J Pharmacol Exp Ther; 2000 Jan; 292(1):238-46. PubMed ID: 10604953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiplatelet activity of [5-(2-methoxy-5-chlorophenyl)furan-2-ylcarbonyl]guanidine (KR-32570), a novel sodium/hydrogen exchanger-1 and its mechanism of action.
    Lee KS; Park JW; Jin YR; Jung IS; Cho MR; Yi KY; Yoo SE; Chung HJ; Yun YP; Park TK; Shin HS
    Arch Pharm Res; 2006 May; 29(5):375-83. PubMed ID: 16756082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostaglandin endoperoxides, thromboxane A2 and adenosine diphosphate in collagen-induced aggregation of rabbit platelets.
    Lewis GP; Watts IS
    Br J Pharmacol; 1982 Apr; 75(4):623-31. PubMed ID: 6802211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-platelet activity of KR-32560, a novel sodium/hydrogen exchanger-1 inhibitor.
    Lee KS; Jin YR; Lee JJ; Lim Y; Son DJ; Lee CK; Yi KY; Yoo SE; Shin HS; Yun YP
    Pharmacol Res; 2006 Mar; 53(3):265-70. PubMed ID: 16420980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thromboxane A2 synthase inhibition and thromboxane A2 receptor blockade by 2-[(4-cyanophenyl)amino]-3-chloro-1,4-naphthalenedione (NQ-Y15) in rat platelets.
    Chang TS; Kim HM; Lee KS; Khil LY; Mar WC; Ryu CK; Moon CK
    Biochem Pharmacol; 1997 Jul; 54(2):259-68. PubMed ID: 9271330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological characterization of cinnamophilin, a novel dual inhibitor of thromboxane synthase and thromboxane A2 receptor.
    Yu SM; Wu TS; Teng CM
    Br J Pharmacol; 1994 Mar; 111(3):906-12. PubMed ID: 8019768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiplatelet effect by p-cresol, a uremic and environmental toxicant, is related to inhibition of reactive oxygen species, ERK/p38 signaling and thromboxane A2 production.
    Chang MC; Wang TM; Yeung SY; Jeng PY; Liao CH; Lin TY; Lin CC; Lin BR; Jeng JH
    Atherosclerosis; 2011 Dec; 219(2):559-65. PubMed ID: 21993412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The novel prostaglandin I2 mimetic ONO-1301 escapes desensitization in an antiplatelet effect due to its inhibitory action on thromboxane A2 synthesis in mice.
    Kashiwagi H; Yuhki K; Kojima F; Kumei S; Takahata O; Sakai Y; Narumiya S; Ushikubi F
    J Pharmacol Exp Ther; 2015 May; 353(2):269-78. PubMed ID: 25740898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.